Gut microbiome emerges as key clue to cancer drug side effects
Researchers at the South Australian Health and Medical Research Institute have identified how the gut microbiome influences side effects of the cancer drug bortezomib. The study links the treatment to nerve-immune signaling changes, offering a potential path to mitigating painful neuropathy and gastrointestinal issues for patients.
Why it matters
Understanding the biological mechanisms behind chemotherapy side effects can significantly improve the quality of life and treatment adherence for cancer patients.
by South Australian Health and Medical Research Institute
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pixabay/CC0 Public Domain New research has uncovered why one of the most widely used treatments for multiple myeloma can cause debilitating nerve and gastrointestinal side effects, marking a significant step toward preventing them.
A collaboration among four research groups based at the South Australian Health and Medical Research Institute (SAHMRI)—the Myeloma Research Laboratory, Supportive Oncology Research Group, Visceral Pain Research Group and Systems Immunology Group—has investigated how the gut microbiome influences the side effects of bortezomib, a cornerstone treatment for the disease.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in